Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Net Cash Flow (2019 - 2025)

Quantum Biopharma's Net Cash Flow history spans 6 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 49.25% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.1 million, a 152.61% decrease, with the full-year FY2025 number at -$4.1 million, down 226.3% from a year prior.
  • Net Cash Flow hit $1.5 million in Q4 2025 for Quantum Biopharma, up from -$1.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for QNTM hit a ceiling of $9.7 million in Q2 2022 and a floor of -$42.5 million in Q4 2022.
  • Historically, Net Cash Flow has averaged -$2.3 million across 4 years, with a median of $2.2 million in 2024.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 2402.58% in 2021 and later tumbled 153.26% in 2025.
  • Tracing QNTM's Net Cash Flow over 4 years: stood at -$37.4 million in 2021, then fell by 13.69% to -$42.5 million in 2022, then soared by 106.76% to $2.9 million in 2024, then crashed by 49.25% to $1.5 million in 2025.
  • Business Quant data shows Net Cash Flow for QNTM at $1.5 million in Q4 2025, -$1.5 million in Q3 2025, and -$659407.0 in Q2 2025.